Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation - Wikidata - wikimedia - TriplyDB

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation

http://www.wikidata.org/entity/Q36212667

about

Ivacaftor for patients with cystic fibrosis Update in Cystic Fibrosis 2014 Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications Animal Models of Cystic Fibrosis Pathology: Phenotypic Parallels and Divergences New and emerging targeted therapies for cystic fibrosis Computed tomography dose optimisation in cystic fibrosis: A review Targeted therapies to improve CFTR function in cystic fibrosis Cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis: current perspectives CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis Current and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its Symptoms A functional CFTR assay using primary cystic fibrosis intestinal organoids Harnessing public domain data to discover and validate therapeutic targets.Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for ivacaftor therapy in the context of CFTR genotype In vivo and in vitro ivacaftor response in cystic fibrosis patients with residual CFTR function: N-of-1 studies.Cystic fibrosis transmembrane conductance regulator mutations at a referral center for cystic fibrosis.CFTR Modulators for the Treatment of Cystic Fibrosis.Cystic fibrosis transmembrane conductance regulator (CFTR) potentiators protect G551D but not ΔF508 CFTR from thermal instability.State of progress in treating cystic fibrosis respiratory disease.Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.Apical CFTR expression in human nasal epithelium correlates with lung disease in cystic fibrosis.Ivacaftor: a novel mutation modulating drug Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis.PharmGKB summary: very important pharmacogene information for CFTR Recent advances in understanding and managing cystic fibrosis transmembrane conductance regulator dysfunction.Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.Improved fluorescence assays to measure the defects associated with F508del-CFTR allow identification of new active compounds.Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.Ivacaftor: a novel gene-based therapeutic approach for cystic fibrosis Acute administration of ivacaftor to people with cystic fibrosis and a G551D-CFTR mutation reveals smooth muscle abnormalities Cystic fibrosis: a model system for precision medicine.Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.Progress in cystic fibrosis and the CF Therapeutics Development Network Functional Rescue of F508del-CFTR Using Small Molecule Correctors An update of childhood genetic disorders.From pipeline to patient: new developments in cystic fibrosis therapeutics.Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.Repairing mutated proteins--development of small molecules targeting defects in the cystic fibrosis transmembrane conductance regulator.Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.Cystic fibrosis transmembrane regulator correctors and potentiators.

P2860

Q22305938-C0B8033F-DB09-4EA8-A0B6-1076B754372A Q22306307-8140F8DF-A4F6-4BE9-9FEC-356E136FFBA4 Q24187139-120F6BCF-18DB-49C8-9F6C-DBA59FB87362 Q26747065-881CCF1C-0868-4685-97CA-1472F0CCEC57 Q26747210-11F5A346-9BEB-4F1D-A573-B6BEB917E56D Q26749278-9064F0F1-AE03-42B6-BDF3-315EA40BE82C Q26751283-B67467C3-C9BD-4CF4-9311-2AFC555448FB Q26781441-10887D20-4B6D-4A80-B845-B2EF99E5BE69 Q28073063-8AE58AB8-1586-4FF1-BCF6-B23B03827F66 Q28073996-EE43BD79-163A-4CFC-B920-5F251203411F Q28077411-93ADD25B-1327-4658-857B-A560350E8137 Q28291898-F41AD587-9D98-4B33-AB03-2A7A993F6248 Q30491667-2C550719-36EB-4B9B-99D4-AD4A34C1B569 Q33633486-42B85172-E42A-41DD-A0AC-59EF39921755 Q33769791-F5897F9C-AC0E-40B6-9B13-DEB9933EB790 Q33824191-729CD03E-FC98-4A48-A979-3A7507166518 Q33920366-250C438C-457F-4633-841B-59FE35C329B9 Q34155612-4549B34E-E0CE-401F-8505-AD91B25D49FF Q34375926-2A4A7130-ADD7-4990-91B2-D3A40E3AE959 Q34496122-E1842B5A-70A6-450C-A956-45DE9916AE86 Q34618363-ADB9D49B-E03F-4EE6-A650-B214AE60D1F3 Q34667499-5809C679-8FC7-4D67-B74A-D017DCF75BB4 Q34748891-37AFA845-8209-4E0D-9BC8-E2EECE35FF40 Q35108743-9CB55A4B-0A34-4C35-B67C-8689C4142D47 Q35659323-94905824-CE31-44A5-892C-90C75579AAF8 Q35743348-5775BF76-CA84-42C0-BB90-4B8290833F3B Q36251047-9D01E5E0-79F6-4F9D-A9B6-DAFEC8ECD172 Q36609344-DDB2FEE1-F55B-4ED9-8072-F7BDBC47E061 Q36765007-AEC34750-05C8-4428-9B67-E1B430CAFD83 Q36865792-7B800659-4A52-4F32-B411-A89DBE093E74 Q37097931-2D04896C-FE26-4904-9C08-67BCBDB3CC4C Q37164477-253B4E5F-2330-45C3-B241-6A2F54B14874 Q37209004-FC2A4EFF-634E-4E3A-8896-63B180868FFF Q38051325-D6C1E991-BA6B-4B30-92B4-7D90B408CDBF Q38072145-0AAF00E2-074A-4E9D-989F-A867FA3E5B39 Q38078451-C30D46D3-D1F9-44B7-8E0C-F68AC2979E6B Q38094297-6CCDDD11-F6FB-407C-8A28-97A5BC5E238B Q38097952-AF4C3D73-1132-4259-BC97-8C8763568079 Q38113749-19BE7F48-432D-4651-9F2C-04AACCD5FF94 Q38118742-DBE55748-6EE6-46D8-B061-ED237934B6FC

P2860

Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation

http://www.wikidata.org/entity/Q36212667

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Ivacaftor in subjects with cys ...... for the F508del-CFTR mutation

@ast

Ivacaftor in subjects with cys ...... for the F508del-CFTR mutation

@en

type

label

Ivacaftor in subjects with cys ...... for the F508del-CFTR mutation

@ast

Ivacaftor in subjects with cys ...... for the F508del-CFTR mutation

@en

prefLabel

Ivacaftor in subjects with cys ...... for the F508del-CFTR mutation

@ast

Ivacaftor in subjects with cys ...... for the F508del-CFTR mutation

@en

P1433

Q36212667-F4895D24-6FE2-4490-B259-7510B666006F

P1476

Q36212667-D4823AC3-A2A2-474D-AC1D-3F593712AC3E

P2093

Q36212667-0639D5A2-F0A9-4C2E-B736-CAF065675B8D

Q36212667-3A250278-2CEB-479A-B3A7-CCE0C9DB5B73

Q36212667-7B3D01EB-2F07-4B2F-8D3E-681F96C4C254

Q36212667-A8857B15-79FB-4DB6-AC91-550B1B07E788

Q36212667-B6DDDE13-9E67-470A-80D7-6C24D92CF20B

Q36212667-EB24DDD5-DEF1-44DA-A334-6BBDE075C03F

Q36212667-F0D14B55-4975-45CE-8CDD-184A5F104AA1

P2860

Q36212667-04EEF6EC-12C0-4673-9472-18B6ADA4AB2D

Q36212667-40EA0AED-B4BA-4A76-8BC3-B6919652822C

Q36212667-4B3D349C-5574-4771-B107-4A002BB6D6DC

Q36212667-5147E729-B58A-423B-A8B9-498E2CB6A6E4

Q36212667-61C3A89B-B08F-47CF-B3EB-81398ACB972A

Q36212667-6421C0A1-61F3-4993-85B3-18A313C2F174

Q36212667-710F66AB-85A4-493C-AB60-FD81E866560C

Q36212667-91574E7A-FD8B-4126-A0F9-5A1D4F389D81

Q36212667-9A5FDFFD-C696-437B-86D4-E0F49902CE59

Q36212667-C05AD7DF-FAC8-407C-9871-568ECAAA78C8

P304

Q36212667-D7B57862-0286-44C6-81CF-4B9D18754662

P31

Q36212667-A2028313-0275-44B1-AD5A-6A6DC1C96F9D

P356

Q36212667-FCB7CB82-D088-483E-A2A9-933CF6820015

P407

Q36212667-1A9FC6FC-7DA9-4C3B-AF4F-6B297049EE55

P433

Q36212667-39046370-A3F4-4431-99EE-A83C56AF83F4

P478

Q36212667-7D674616-61F9-45D0-AB44-9434E26C71CC

P50

Q36212667-E168496D-7A36-4B0A-BE4F-D77ACE0C09FF

P577

Q36212667-5E4DEAA4-FB16-482E-BA69-C0A5B08EFC0F

P698

Q36212667-44FDFF7B-8E3E-451A-A3A0-3986D61AA8A4

P921

Q36212667-FA0F184F-2457-48FE-9089-5883DE820779

Q36212667-FCA2D249-4E7E-4505-A8AC-11D1ADF5F850

P932

Q36212667-BAC4BA31-CCDD-46E7-BFF4-35FB8E15EEDB

P356

P1433

P1476

Ivacaftor in subjects with cys ...... for the F508del-CFTR mutation

@en

P2093

Claudia L Ordoñez

http://www.w3.org/2001/XMLSchema#string

David E Geller

http://www.w3.org/2001/XMLSchema#string

Drucy S Borowitz

http://www.w3.org/2001/XMLSchema#string

Haihong Li

http://www.w3.org/2001/XMLSchema#string

Karl Yen

http://www.w3.org/2001/XMLSchema#string

Patrick A Flume

http://www.w3.org/2001/XMLSchema#string

VX 08-770-104 Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of the cystic fibrosis gene: chromosome walking and jumping

Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation

Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770

Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA

Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening

Cystic fibrosis

Standardization of Spirometry, 1994 Update. American Thoracic Society

Identification of the cystic fibrosis gene: genetic analysis

Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study.

Determinants of mild clinical symptoms in cystic fibrosis patients. Residual chloride secretion measured in rectal biopsies in relation to the genotype.

P304

718-724

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1378/CHEST.11-2672

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

142

http://www.w3.org/2001/XMLSchema#string

P50

Theodore G. Liou

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22383668

http://www.w3.org/2001/XMLSchema#string

P921

cystic fibrosis

P932

3435140

http://www.w3.org/2001/XMLSchema#string